Taken together, the findings of this study demonstrated that LTF acted as an oncogenic regulator in GBM by promoting NF-κB signaling pathway activation, extending knowledge on the molecular mechanism of GBM progression and providing new potential therapeutic targets for GBM treatment. The gene discussed is LTF; the disease is glioblastoma.